Many therapeutic trials in DMD exclude non-ambulatory boys and men. Rate of progression in these non-ambulatory patients has been studied but consensus has not been reached for what measures are most reliable and reproducible. Furthermore, any treatment trial would be expected to demonstrate improved function and improvement in quality of life. Therefore, function, strength, and quality of life must be understood and standardized. While the goal of this proposal is to standardize clinical outcomes for therapeutic trials, careful understanding of the progression of DMD in non ambulatory boys may also lead to better medical treatment.
For Non-ambulatory study, boys must be unable to walk without assistive devices for greater than or equal to one year. Age at onset of study for non-ambulatory boys and men: greater than or equal to 7 years through age 22 years. Genetic or biopsy confirmation of dystrophinopathy or clinical diagnosis of DMD with biopsy/genetic confirmation in a primary relative.
Study Type
OBSERVATIONAL
Enrollment
50
Washington University
St Louis, Missouri, United States
Dystrophin gene mutations that predispose to early onset cardiomyopathy
Time frame: 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.